Cost-effectiveness analysis of simeprevir with daclatasvir for non-cirrhotic genotype-1b-naïve patients plus chronic hepatitis C

Expert Review of Pharmacoeconomics & Outcomes Research
Vicente Gimeno-BallesterRamón San Miguel

Abstract

The cost of interferon-free combination therapies remains high to provide widespread access to treatment, regardless of fibrosis stage. To estimate the cost-effectiveness of simeprevir/daclatasvir (SMV/DCV) therapy in treatment-naïve chronic hepatitis C genotype-1b patients with moderate fibrosis. A Markov model was developed to simulate the natural history of chronic hepatitis C progression. The model estimated lifetime healthcare costs and quality-adjusted life-years (QALY) for a cohort of patients from the Spanish National Healthcare System perspective. The cost-effectiveness threshold considered was €40,000/QALY. The treatment strategies analyzed were SMV/DCV, peginterferon/ribavirin/telaprevir, and peginterferon/ribavirin/boceprevir. A sensitivity analysis was carried out. The incremental cost-effectiveness ratios of the SMV/DCV strategy were €23,774/QALY and €28,524/QALY compared with that of telaprevir or boceprevir triple therapy, respectively, for genotype-1b patients with moderate fibrosis. SMV/DCV combination compared with the standard of care previous to the arrival of second-generation direct-acting antivirals fell below generally accepted willingness-to-pay threshold. Results obtained should be supported by ongoin...Continue Reading

References

Oct 9, 2002·American Journal of Epidemiology·Joshua A SalomonSue J Goldie
May 20, 2005·The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care·Uwe SiebertSiegbert Rossol
Oct 13, 2009·Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research·Javier MarMercè Comas
Apr 21, 2010·The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care·Julio López-BastidaJaume Puig-Junoy
Apr 1, 2011·The New England Journal of Medicine·Fred PoordadUNKNOWN SPRINT-2 Investigators
Apr 27, 2011·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Andrew Aronsohn, Donald Jensen
Jun 24, 2011·The New England Journal of Medicine·Ira M JacobsonUNKNOWN ADVANCE Study Team
Aug 10, 2011·Revista española de salud pública·María del Carmen Ramos-Sánchez, Francisco Javier Martín-Gil
Dec 14, 2011·Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research·Rebecca TownsendYong Yuan
Aug 18, 2012·International Journal of Hepatology·Nobuhisa Akamatsu, Yasuhiko Sugawara
Sep 20, 2012·Medical Decision Making : an International Journal of the Society for Medical Decision Making·Uwe SiebertKaren M Kuntz
Sep 25, 2012·Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research·Andrew H BriggsUNKNOWN ISPOR-SMDM Modeling Good Research Practices Task Force
Mar 9, 2013·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Stefan Zeuzem, Federico J Mensa
Mar 28, 2013·BMC Medicine·Don HusereauUNKNOWN CHEERS Task Force
Dec 18, 2013·Journal of Hepatology·UNKNOWN European Association for Study of Liver
Apr 3, 2014·Revista Española De Enfermedades Digestivas : Organo Oficial De La Sociedad Española De Patología Digestiva· Sociedad Española de Patología Digestiva
Apr 24, 2014·Alimentary Pharmacology & Therapeutics·M H MillerJ F Dillon
May 14, 2014·Expert Review of Pharmacoeconomics & Outcomes Research·Michael Wonder
Jan 13, 2015·Expert Review of Pharmacoeconomics & Outcomes Research·James D ChambersPeter J Neumann

❮ Previous
Next ❯

Citations

Oct 27, 2016·Infectious Diseases and Therapy·Roberto Nuño SolinísYuri Sanchez Gonzalez
May 19, 2017·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·X LiE W Chan
Jul 19, 2017·The Annals of Pharmacotherapy·T Joseph MattinglyC Daniel Mullins
Oct 17, 2018·European Journal of Gastroenterology & Hepatology·Kathrin KrügerUNKNOWN Collaborators DHC-R
Feb 23, 2019·Expert Review of Gastroenterology & Hepatology·Jaume Puig-JunoyMíriam Solozabal

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antivirals (ASM)

Antivirals are medications that are used specifically for treating viral infections. Discover the latest research on antivirals here.

Antivirals

Antivirals are medications that are used specifically for treating viral infections. Discover the latest research on antivirals here.